Stay updated on RC48-ADC in HER2+ Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the RC48-ADC in HER2+ Urothelial Cancer Clinical Trial page.

Latest updates to the RC48-ADC in HER2+ Urothelial Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the details of a study evaluating the efficacy and safety of intravenous RC48-ADC for urothelial carcinoma, including inclusion and exclusion criteria. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference30%
- Check34 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check70 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check91 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check99 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to RC48-ADC in HER2+ Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RC48-ADC in HER2+ Urothelial Cancer Clinical Trial page.